Edition:
India

Celgene Corp (CELG.OQ)

CELG.OQ on NASDAQ Stock Exchange Global Select Market

88.15USD
22 Mar 2019
Change (% chg)

$-1.48 (-1.65%)
Prev Close
$89.63
Open
$89.22
Day's High
$89.49
Day's Low
$87.96
Volume
2,681,686
Avg. Vol
2,937,080
52-wk High
$95.30
52-wk Low
$58.61

Latest Key Developments (Source: Significant Developments)

Starboard Opposes Bristol-Myers' Proposed Acquisition Of Celgene
Tuesday, 19 Mar 2019 

March 19 (Reuters) - Bristol-Myers Squibb Co ::STARBOARD ISSUES INVESTOR PRESENTATION OPPOSING BRISTOL-MYERS SQUIBB'S ILL-ADVISED PROPOSED ACQUISITION OF CELGENE.STARBOARD ISSUES INVESTOR PRESENTATION OPPOSING BRISTOL-MYERS SQUIBB'S ILL-ADVISED PROPOSED ACQUISITION OF CELGENE.STARBOARD VALUE SAYS BELIEVES PROPOSED MERGER WITH CELGENE IS NOT IN BEST INTERESTS OF BRISTOL-MYERS SHAREHOLDERS.STARBOARD VALUE SAYS URGES ALL BRISTOL-MYERS SHAREHOLDERS TO REJECT PROPOSED CELGENE TRANSACTION.STARBOARD VALUE SAYS MAILED DEFINITIVE PROXY MATERIALS AND A BLUE PROXY CARD IN CONNECTION WITH BRISTOL-MYERS SQUIBB SPECIAL MEETING OF SHAREHOLDERS.  Full Article

Celgene Provides Update On Abraxane Combination Therapy
Wednesday, 13 Mar 2019 

March 12 (Reuters) - Celgene Corp ::CELGENE PROVIDES UPDATE ON ABRAXANE® COMBINATION THERAPY IN THE TREATMENT OF METASTATIC TRIPLE-NEGATIVE BREAST CANCER AND PANCREATIC CANCER.CELGENE CORP - TECENTRIQ WITH ABRAXANE RECEIVES ACCELERATED APPROVAL FOR PEOPLE WITH PD-L1-POSITIVE, METASTATIC TRIPLE-NEGATIVE BREAST CANCER.CELGENE - PHASE 3 APACT STUDY DID NOT ACHIEVE PRIMARY ENDPOINT.CELGENE CORP - SAFETY PROFILE OBSERVED IN APACT STUDY WAS CONSISTENT WITH PREVIOUSLY REPORTED STUDIES OF ABRAXANE.CELGENE - OVERALL SURVIVAL, A SECONDARY ENDPOINT OF PHASE 3 APACT STUDY, WAS IMPROVED, REACHING NOMINAL STATISTICAL SIGNIFICANCE.  Full Article

U.S. FDA Grants Priority Review For Fedratinib New Drug Application In Myelofibrosis
Tuesday, 5 Mar 2019 

March 5 (Reuters) - Celgene Corp ::U.S. FDA GRANTS PRIORITY REVIEW FOR FEDRATINIB NEW DRUG APPLICATION IN MYELOFIBROSIS.CELGENE CORP - U.S. FOOD & DRUG ADMINISTRATION SETS PRESCRIPTION DRUG USER FEE ACT ACTION DATE FOR SEPT. 3, 2019.CELGENE CORP - PRESCRIPTION DRUG USER FEE ACT ACTION DATE FOR SEPT. 3, 2019.CELGENE CORP - CELGENE ALSO PLANS TO EVALUATE FEDRATINIB IN COMBINATION WITH LUSPATERCEPT.  Full Article

Celgene Corp - CEO Mark Alles' 2018 Total Compensation $16.2 Million Versus $13.1 Million In 2017 - SEC Filing
Saturday, 2 Mar 2019 

March 1 (Reuters) - Celgene Corp ::CELGENE CORP - CEO MARK ALLES' 2018 TOTAL COMPENSATION $16.2 MILLION VERSUS $13.1 MILLION IN 2017 - SEC FILING.CELGENE CORP - CFO DAVID ELKINS' 2018 TOTAL COMPENSATION WAS $13.1 MILLION.  Full Article

Starboard Now Owns 4.4 Mln Bristol-Myers Shares-Filing
Friday, 1 Mar 2019 

Feb 28 (Reuters) - Bristol-Myers Squibb Co ::ACTIVIST HEDGE FUND STARBOARD SAYS NOW OWNS 4.4 MILLION BRISTOL-MYERS SHARES-FILING.  Full Article

Bristol-Myers Squibb Says Celgene Deal Is The Best Path Forward
Thursday, 28 Feb 2019 

Feb 28 (Reuters) - Bristol-Myers Squibb Co ::BRISTOL-MYERS SQUIBB, IN LETTER TO EMPLOYEES ON FEB 27, SAYS "WE ARE VERY DISAPPOINTED BY POSITION OF WELLINGTON MANAGEMENT".BRISTOL-MYERS SQUIBB, IN LETTER TO EMPLOYEES ON FEB. 27, SAYS "BELIEVE THAT THE CELGENE TRANSACTION IS THE BEST PATH FORWARD FOR OUR COMPANY".  Full Article

Prothena Corporation Q4 Loss Per Share $0.56
Friday, 15 Feb 2019 

Prothena Corporation Plc ::PROTHENA REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS, AND PROVIDES FINANCIAL GUIDANCE AND RESEARCH AND DEVELOPMENT UPDATE.Q4 LOSS PER SHARE $0.56.Q4 EARNINGS PER SHARE ESTIMATE $-0.94 -- REFINITIV IBES DATA.EXPECTS FULL YEAR 2019 NET CASH BURN FROM OPERATING AND INVESTING ACTIVITIES TO BE $64 MILLION TO $72 MILLION.QUARTER-END CASH AND RESTRICTED CASH POSITION OF $431.7 MILLION PROVIDES FUNDING TO ADVANCE NEUROSCIENCE PIPELINE.ENTERED INTO GLOBAL NEUROSCIENCE RESEARCH & DEVELOPMENT COLLABORATION WITH CELGENE.  Full Article

Celgene Q4 Earnings Per Share $1.50
Thursday, 31 Jan 2019 

Jan 31 (Reuters) - Celgene Corp ::CELGENE REPORTS FOURTH QUARTER AND FULL YEAR 2018 OPERATING AND FINANCIAL RESULTS.Q4 REVENUE $4.037 BILLION VERSUS REFINITIV IBES ESTIMATE OF $3.99 BILLION.Q4 EARNINGS PER SHARE $1.50.Q4 EARNINGS PER SHARE ESTIMATE $2.32 -- REFINITIV IBES DATA.REAFFIRMING 2020 FINANCIAL OUTLOOK.REVLIMID SALES FOR Q4 INCREASED 16 PERCENT TO $2,549 MILLION.OZANIMOD U.S. AND EU REGULATORY SUBMISSIONS ON-TRACK FOR Q1 2019.OTEZLA SALES IN Q4 WERE $448 MILLION, A 21 PERCENT INCREASE YEAR-OVER-YEAR.QTRLY ADJUSTED EARNINGS PER SHARE $2.39.BRISTOL-MYERS SQUIBB AND CELGENE EXPECT TO CLOSE TRANSACTION IN Q3 OF 2019.SEES 2019 GAAP DILUTED EPS $8.40 TO $9.08.2019 GUIDANCE FOR TOTAL REVENUE AND NET PRODUCT SALES OF REVLIMID & OTEZLA UNCHANGED FROM GUIDANCE PROVIDED ON JAN. 7.FY2019 EARNINGS PER SHARE VIEW $10.42, REVENUE VIEW $17.00 BILLION -- REFINITIV IBES DATA.  Full Article

Triphase Accelerator - Entered into new strategic partnership with Celgene Corp
Tuesday, 29 Jan 2019 

Jan 29 (Reuters) - Celgene Corp ::TRIPHASE ACCELERATOR - ENTERED INTO NEW STRATEGIC PARTNERSHIP WITH CELGENE CORPORATION.TRIPHASE ACCELERATOR - FOCUS OF COLLABORATION TO BE ON PRE-CLINICAL THERAPEUTIC BY OICR FOR LEUKEMIA & OTHER BLOOD CANCERS, SPECIFICALLY TARGETING WDR5 PROTEIN.TRIPHASE ACCELERATOR- CELGENE TO PAY UPFRONT AMOUNT OF $40 MILLION.  Full Article

Facit And Triphase Accelerator Announce New Partnership With Celgene
Tuesday, 29 Jan 2019 

Jan 29 (Reuters) - Celgene Corp ::FACIT AND TRIPHASE ACCELERATOR ANNOUNCE NEW PARTNERSHIP WITH CELGENE FOR WDR5 LEUKEMIA THERAPY.TRIPHASE ACCELERATOR - CELGENE HAS OPTION TO ACQUIRE TRPH-395 FROM TRIPHASE ACCELERATOR.TRIPHASE ACCELERATOR - CELGENE TO PAY UPFRONT OF $40 MILLION, UPON EXERCISE OF OPTION, CELGENE TO PAY UP TO $940M IN CONTINGENT DEVELOPMENT, MILESTONES.TRIPHASE ACCELERATOR - ADDITIONAL PAYMENTS FROM CELGENE FOR SALES-BASED ROYALTIES ARE ALSO POSSIBLE.  Full Article

U.S. court rejects Alvogen's patent challenge for Celgene's cancer drug

The U.S. patent office on Thursday rejected a filing by Alvogen Pine Brook Llc for a review challenging patents on Celgene Corp's blockbuster myeloma drug Revlimid.